CelGro gains Australian reimbursement
Filed with ASX · · 3 pages · English
● CelGro® Dental granted inclusion on the Australian Prostheses List ● The Prostheses List defines the minimum value of benefit private insurers pay for CelGro® Dentalused in approved dental bone and soft tissue repair procedures ● Positions Orthocell favorably on its pathway to secure distribution partners Perth, Australia; 03 March 2021: Regenerative medicine company Orthocell Limited (ASX:OCC,
Story so far
Earlier from Orthocell
- Orthocell receives new US patent for CelGro
- CelGro Recommended for Reimbursement
- Orthocell Receives A$2.3m R&D Tax Incentive Refund
- Orthocell Receives US Market Clearance
- Orthocell Receives First US CelGro Product Approval
Later from Orthocell
- CelGro Study Results Open Up New US Market Access Strategy
- New Collagen Rope Patent for CelGro Platform Technology
- OCC Secures Patents for Sutureless Repair of Soft Tissue
- Positive CelGro Nerve Regeneration Results
- Orthocell Appoints Exclusive Distributor in Australia
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell